Highlights
- RAD is conducting RAD 204 Phase 1 therapeutic study that targets PDL1-positive non-small cell lung cancer.
- The study will be conducted at the Princess Alexandra Hospital, Brisbane.
- Recently, the company has expanded the geographic availability of the trial after receiving HREC approval.
Radiopharm Theranostics Limited (ASX: RAD) is an ASX-listed radiotherapeutics company focused on developing a platform of innovative radiopharmaceutical products for therapeutic and diagnostic applications in the areas of unmet medical demand. One of the areas of unmet medical need that company targets is non-small lung cancer.
Under a research partnership with Australia’s Nuclear Science and Technology Organisation (ANSTO), the company has undertaken a trial comprising-
Under the trial, ANSTO would supply isotope non-carrier-added lutetium-177 (Lu-177) for research across Australia.
More about the Nanomab-PDL-1Phase 1 therapeutic trial
The title of the study is-
It is a first-in-human dose escalation trial of 177Lu-RAD 204, designed to assess the efficacy and safety of this radiotherapeutic in patients with advanced NSCLC.
At Princess Alexandra Hospital in Brisbane, the study will be conducted with the assistance of GenesisCare, an oncology care providing company.
Progress of the trial
On 22 December 2023, the company announced that the site initiation visit was finalised for the study. As of this date, pre-screening of eligible individuals was going on at the clinical site, projecting the commitment and readiness to dose patients with 177Lu-RAD 204.
On 27 December 2023, the Hollywood Private Hospital in Perth provided Human Research Ethics Committee (HREC) approval. With this approval, Hollywood Private Hospital will become second site for the trial in Australia. Addition of the Perth site is expected to boost the recruitment as the geographic availability of the study expands.
RAD shares traded at AU$0.075 apiece at the time of writing on 24 January 2024.